SENSUS HEALTHCARE INC (SRTS) Stock Fundamental Analysis
NASDAQ:SRTS - Nasdaq - US81728J1097 - Common Stock - Currency: USD
Overall SRTS gets a fundamental rating of 6 out of 10. We evaluated SRTS against 187 industry peers in the Health Care Equipment & Supplies industry. SRTS has an excellent financial health rating, but there are some minor concerns on its profitability. SRTS has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year SRTS was profitable.
SRTS had a positive operating cash flow in the past year.
Of the past 5 years SRTS 4 years were profitable.
In the past 5 years SRTS always reported negative operating cash flow.
1.2 Ratios
SRTS has a better Return On Assets (2.99%) than 78.61% of its industry peers.
SRTS has a Return On Equity of 3.40%. This is in the better half of the industry: SRTS outperforms 76.47% of its industry peers.
With a decent Return On Invested Capital value of 3.54%, SRTS is doing good in the industry, outperforming 72.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.99% | ||
| ROE | 3.4% | ||
| ROIC | 3.54% |
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 4.56%, SRTS is doing good in the industry, outperforming 76.47% of the companies in the same industry.
SRTS's Profit Margin has been stable in the last couple of years.
SRTS's Operating Margin of 6.48% is fine compared to the rest of the industry. SRTS outperforms 73.80% of its industry peers.
In the last couple of years the Operating Margin of SRTS has grown nicely.
The Gross Margin of SRTS (56.02%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SRTS has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.48% | ||
| PM (TTM) | 4.56% | ||
| GM | 56.02% |
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SRTS is destroying value.
SRTS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SRTS remains at a similar level compared to 5 years ago.
SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SRTS has an Altman-Z score of 8.51. This indicates that SRTS is financially healthy and has little risk of bankruptcy at the moment.
SRTS has a better Altman-Z score (8.51) than 87.70% of its industry peers.
SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.51 |
ROIC/WACC0.39
WACC9.03%
2.3 Liquidity
SRTS has a Current Ratio of 8.06. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
SRTS has a Current ratio of 8.06. This is amongst the best in the industry. SRTS outperforms 88.24% of its industry peers.
SRTS has a Quick Ratio of 5.74. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SRTS (5.74) is better than 86.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.06 | ||
| Quick Ratio | 5.74 |
3. Growth
3.1 Past
The earnings per share for SRTS have decreased strongly by -65.52% in the last year.
The Earnings Per Share has been growing by 18.56% on average over the past years. This is quite good.
The Revenue has grown by 24.73% in the past year. This is a very strong growth!
SRTS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.93% yearly.
EPS 1Y (TTM)-65.52%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-214.29%
Revenue 1Y (TTM)24.73%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%-21.75%
3.2 Future
SRTS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.22% yearly.
SRTS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.44% yearly.
EPS Next Y-16.87%
EPS Next 2Y23.18%
EPS Next 3Y11.94%
EPS Next 5Y-5.22%
Revenue Next Year8.01%
Revenue Next 2Y19.2%
Revenue Next 3Y17.25%
Revenue Next 5Y13.44%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 47.40, which means the current valuation is very expensive for SRTS.
Based on the Price/Earnings ratio, SRTS is valued a bit cheaper than the industry average as 68.98% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of SRTS to the average of the S&P500 Index (26.34), we can say SRTS is valued expensively.
SRTS is valuated cheaply with a Price/Forward Earnings ratio of 7.81.
95.19% of the companies in the same industry are more expensive than SRTS, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, SRTS is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.4 | ||
| Fwd PE | 7.81 |
4.2 Price Multiples
74.87% of the companies in the same industry are more expensive than SRTS, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SRTS indicates a rather cheap valuation: SRTS is cheaper than 89.30% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.84 | ||
| EV/EBITDA | 19.53 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.18%
EPS Next 3Y11.94%
5. Dividend
5.1 Amount
No dividends for SRTS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.74
-0.08 (-1.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners25.85%
Inst Owner Change-13.59%
Ins Owners16.6%
Ins Owner Change2.22%
Market Cap77.97M
Analysts81.82
Price Target11.22 (136.71%)
Short Float %6.58%
Short Ratio9.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-295.1%
Min EPS beat(2)-561.36%
Max EPS beat(2)-28.84%
EPS beat(4)2
Avg EPS beat(4)129.07%
Min EPS beat(4)-561.36%
Max EPS beat(4)786.28%
EPS beat(8)5
Avg EPS beat(8)82.35%
EPS beat(12)6
Avg EPS beat(12)40.08%
EPS beat(16)9
Avg EPS beat(16)46.99%
Revenue beat(2)2
Avg Revenue beat(2)15.6%
Min Revenue beat(2)13.08%
Max Revenue beat(2)18.13%
Revenue beat(4)4
Avg Revenue beat(4)26.89%
Min Revenue beat(4)13.08%
Max Revenue beat(4)47%
Revenue beat(8)6
Avg Revenue beat(8)29.4%
Revenue beat(12)7
Avg Revenue beat(12)15.31%
Revenue beat(16)10
Avg Revenue beat(16)16.94%
PT rev (1m)-8.33%
PT rev (3m)-15.38%
EPS NQ rev (1m)-12.5%
EPS NQ rev (3m)-39.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.01%
Revenue NQ rev (1m)6.93%
Revenue NQ rev (3m)-3.7%
Revenue NY rev (1m)2.35%
Revenue NY rev (3m)-4.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.4 | ||
| Fwd PE | 7.81 | ||
| P/S | 1.97 | ||
| P/FCF | 16.84 | ||
| P/OCF | 16.66 | ||
| P/B | 1.47 | ||
| P/tB | 1.47 | ||
| EV/EBITDA | 19.53 |
EPS(TTM)0.1
EY2.11%
EPS(NY)0.61
Fwd EY12.8%
FCF(TTM)0.28
FCFY5.94%
OCF(TTM)0.28
OCFY6%
SpS2.4
BVpS3.22
TBVpS3.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.99% | ||
| ROE | 3.4% | ||
| ROCE | 4.78% | ||
| ROIC | 3.54% | ||
| ROICexc | 5.5% | ||
| ROICexgc | 5.5% | ||
| OM | 6.48% | ||
| PM (TTM) | 4.56% | ||
| GM | 56.02% | ||
| FCFM | 11.72% |
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-12.67%
ROICexcg growth 5YN/A
ROICexc growth 3Y-12.29%
ROICexc growth 5YN/A
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
F-Score6
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 10.89% | ||
| Cap/Sales | 0.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 155.14% | ||
| Profit Quality | 257.02% | ||
| Current Ratio | 8.06 | ||
| Quick Ratio | 5.74 | ||
| Altman-Z | 8.51 |
F-Score6
WACC9.03%
ROIC/WACC0.39
Cap/Depr(3y)54.52%
Cap/Depr(5y)46.98%
Cap/Sales(3y)0.65%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-65.52%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-214.29%
EPS Next Y-16.87%
EPS Next 2Y23.18%
EPS Next 3Y11.94%
EPS Next 5Y-5.22%
Revenue 1Y (TTM)24.73%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%-21.75%
Revenue Next Year8.01%
Revenue Next 2Y19.2%
Revenue Next 3Y17.25%
Revenue Next 5Y13.44%
EBIT growth 1Y-52.94%
EBIT growth 3Y25.22%
EBIT growth 5YN/A
EBIT Next Year-63.88%
EBIT Next 3Y27.1%
EBIT Next 5Y48.86%
FCF growth 1Y142.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y144.6%
OCF growth 3YN/A
OCF growth 5YN/A